AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Procyon Advisors LLC

Procyon Advisors LLC grew its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 12.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,695 shares of the company's stock after acquiring an additional 3,842 shares during the period. Procyon Advisors LLC's holdings in AstraZeneca were worth $2,208,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Bank of Montreal Can raised its holdings in AstraZeneca by 109.6% in the third quarter. Bank of Montreal Can now owns 3,071,333 shares of the company's stock valued at $238,397,000 after acquiring an additional 1,605,758 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of AstraZeneca by 8.7% in the 3rd quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company's stock valued at $1,492,649,000 after purchasing an additional 1,522,715 shares in the last quarter. Farallon Capital Management LLC lifted its position in shares of AstraZeneca by 65.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,409,718 shares of the company's stock worth $187,934,000 after purchasing an additional 950,000 shares during the last quarter. Erste Asset Management GmbH acquired a new position in shares of AstraZeneca during the third quarter worth $72,437,000. Finally, Fisher Asset Management LLC increased its holdings in AstraZeneca by 5.3% in the third quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company's stock valued at $816,509,000 after buying an additional 524,175 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company's stock.

AstraZeneca Stock Performance

NASDAQ:AZN traded down $0.31 during midday trading on Friday, reaching $66.60. The stock had a trading volume of 5,419,360 shares, compared to its average volume of 4,140,949. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The stock has a market cap of $206.50 billion, a P/E ratio of 31.87, a P/E/G ratio of 1.05 and a beta of 0.46. The firm has a fifty day simple moving average of $66.11 and a two-hundred day simple moving average of $74.49. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating analysts' consensus estimates of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm's revenue was up 18.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.87 earnings per share. On average, equities analysts expect that AstraZeneca PLC will post 4.11 EPS for the current year.

Analyst Upgrades and Downgrades

AZN has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a "sell" rating to a "hold" rating in a report on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a "sell" rating to a "neutral" rating in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, AstraZeneca has an average rating of "Buy" and a consensus price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.